Prucalopride Holsten
Selective 5-HT4 Receptor Agonist for Chronic Constipation
Quick Facts About Prucalopride Holsten
Key Takeaways About Prucalopride Holsten
- For laxative-resistant constipation: Prucalopride Holsten is specifically indicated for chronic constipation in adults when standard laxatives (such as osmotic and stimulant laxatives) have not worked well enough
- Once-daily dosing: The standard adult dose is 2 mg once daily (two 1 mg tablets), taken at any time with or without food; elderly patients (>65 years) and those with severe kidney or liver disease start at 1 mg daily (one tablet)
- Side effects are usually temporary: Headache, nausea, diarrhoea, and abdominal pain are the most common side effects but typically resolve within the first few days of treatment
- Reassess after 4 weeks: Your doctor should evaluate whether treatment is still beneficial after the first four weeks and at regular intervals thereafter
- Not for children: Prucalopride Holsten is approved for use in adults only and should not be given to children or adolescents under 18 years of age
What Is Prucalopride Holsten and What Is It Used For?
Prucalopride Holsten is a prescription medication used to treat chronic constipation in adults when conventional laxatives have failed to provide satisfactory results. It belongs to a class of drugs called gastrointestinal prokinetic agents and works by selectively stimulating serotonin 5-HT4 receptors in the intestinal wall to restore normal bowel function.
Prucalopride Holsten contains the active substance prucalopride (as prucalopride succinate). It is a highly selective, high-affinity agonist of the serotonin 5-HT4 receptor, a molecular target found predominantly on neurons and smooth muscle cells within the gastrointestinal tract. By activating these receptors, prucalopride triggers the peristaltic reflex – the coordinated wave-like contractions that propel food and waste through the intestines – thereby accelerating colonic transit and promoting regular, complete bowel movements.
Chronic constipation is a common and often debilitating condition affecting an estimated 10–15% of the adult population worldwide, with a higher prevalence in women and the elderly. It is defined as having fewer than three spontaneous complete bowel movements per week, often accompanied by straining, hard stools, a sensation of incomplete evacuation, and abdominal discomfort. While lifestyle measures (increased fibre intake, adequate hydration, regular physical activity) and standard laxatives are the first line of treatment, a significant proportion of patients – estimated at 40–50% – remain dissatisfied with conventional laxative therapy.
Prucalopride fills an important therapeutic gap for these patients. Unlike bulk-forming laxatives (which increase stool volume), osmotic laxatives (which draw water into the bowel), or stimulant laxatives (which directly irritate the intestinal mucosa), prucalopride works by enhancing the body's natural motility mechanisms. This approach can be particularly beneficial for patients with slow-transit constipation, where the fundamental problem is impaired colonic motility rather than inadequate fibre or fluid intake.
Clinical trials have consistently demonstrated that prucalopride significantly increases the number of spontaneous complete bowel movements per week compared with placebo. In the pivotal phase III trials, approximately 24–30% of patients treated with prucalopride 2 mg achieved three or more spontaneous complete bowel movements per week (the primary endpoint), compared with approximately 12% of those receiving placebo. Improvements were also seen in stool consistency, straining, satisfaction with bowel function, and overall quality of life.
Prucalopride was first approved in Europe in 2009 and has since been authorised in over 80 countries worldwide. The European Medicines Agency (EMA) and the American Gastroenterological Association (AGA) recognise prucalopride as an effective treatment option for chronic idiopathic constipation. Prucalopride Holsten is a generic formulation distributed by Holsten Pharma, containing the same active substance as the originator product (Resolor) and has demonstrated bioequivalence.
What Should You Know Before Taking Prucalopride Holsten?
Before starting Prucalopride Holsten, tell your doctor about all your medical conditions, particularly kidney disease, liver disease, inflammatory bowel disease, and any intestinal problems. Prucalopride should not be used during pregnancy, and breastfeeding is not recommended during treatment.
Contraindications
You should not take Prucalopride Holsten if any of the following apply to you:
- Allergy to prucalopride or any of the other ingredients in this medicine (listed in the Ingredients section below) – symptoms of an allergic reaction may include skin rash, itching, swelling of the face or throat, or difficulty breathing
- Kidney failure requiring dialysis – prucalopride is partly excreted by the kidneys, and dialysis-dependent patients have not been adequately studied
- Intestinal perforation or obstruction – a hole in or blockage of the intestinal wall, which could be worsened by stimulating bowel motility
- Severe inflammatory bowel conditions – including Crohn's disease, ulcerative colitis, or toxic megacolon/megarectum, where increased motility could be dangerous
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before taking Prucalopride Holsten if you have or have had any of the following conditions:
- Severe kidney disease (not requiring dialysis) – a lower dose of 1 mg daily is recommended, as prucalopride clearance is reduced in patients with significant renal impairment
- Severe liver disease – a lower starting dose of 1 mg daily is recommended due to the potential for altered drug metabolism
- Serious underlying medical conditions – if you are currently under medical supervision for a serious condition such as lung or heart disease, neurological problems, psychiatric disorders, cancer, HIV/AIDS, or hormonal disorders, tell your doctor before starting prucalopride
Your doctor should reassess the benefits of continued treatment after the first four weeks and periodically thereafter. If prucalopride has not provided meaningful improvement in your symptoms after four weeks of treatment, the reasons for this should be investigated and the decision to continue treatment should be reconsidered.
If you experience very severe diarrhoea while taking prucalopride, the effectiveness of oral contraceptive pills may be reduced. An additional method of contraception is recommended. Refer to the patient information leaflet of your oral contraceptive for further guidance.
Pregnancy and Breastfeeding
If you are pregnant, think you might be pregnant, plan to become pregnant, or are breastfeeding, consult your doctor or pharmacist before using Prucalopride Holsten.
Pregnancy: Prucalopride Holsten should not be used during pregnancy. The effects of prucalopride on human pregnancy have not been established, and preclinical studies do not provide sufficient reassurance regarding potential risks to the developing foetus. If you are of childbearing potential, use a reliable method of contraception while taking Prucalopride Holsten. If you discover you are pregnant during treatment, stop taking the medication and contact your doctor immediately.
Breastfeeding: Prucalopride passes into breast milk. Because the potential effects on the nursing infant are unknown, breastfeeding is not recommended during treatment with Prucalopride Holsten. Discuss with your doctor whether to discontinue breastfeeding or to discontinue the medication, taking into account the importance of the drug to your health.
Driving and Operating Machinery
Prucalopride Holsten is unlikely to affect your ability to drive or use machines. However, dizziness and fatigue have been reported, particularly during the first day of treatment. If you experience these symptoms, do not drive or operate machinery until they resolve. You are responsible for assessing your own fitness to perform tasks requiring alertness. Consider all effects and side effects described in this guide before driving or operating equipment.
Lactose Content
Prucalopride Holsten tablets contain lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The amount of lactose in each tablet is relatively small, but patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
How Does Prucalopride Holsten Interact with Other Drugs?
Prucalopride has a relatively low potential for drug interactions compared with many other gastrointestinal medications. It does not significantly inhibit or induce major drug-metabolising enzymes. However, some interactions have been identified, particularly with drugs that affect the P-glycoprotein transport system or CYP3A4 enzyme.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including non-prescription products and herbal supplements. Although prucalopride has a favourable interaction profile, certain combinations may require monitoring or dose adjustment.
Prucalopride is partly metabolised by CYP3A4 in the liver, and approximately 60% of the dose is excreted unchanged by the kidneys. It is also a substrate of the P-glycoprotein (P-gp) efflux transporter. Drugs that strongly inhibit these pathways can increase prucalopride blood levels, while potent inducers may decrease its effectiveness. However, because a large fraction of prucalopride is eliminated renally without metabolism, the clinical significance of most interactions is limited.
Known Drug Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Ketoconazole | Antifungal (CYP3A4 / P-gp inhibitor) | Increases prucalopride plasma levels by approximately 40% | No dose adjustment required; monitor for increased side effects |
| Erythromycin | Macrolide antibiotic (CYP3A4 inhibitor, prokinetic) | May increase prucalopride levels; additive prokinetic effects | Monitor for gastrointestinal side effects; use caution |
| Paroxetine | SSRI antidepressant | No clinically significant pharmacokinetic interaction demonstrated | No dose adjustment required |
| Cimetidine | H2-receptor antagonist | No clinically significant pharmacokinetic interaction demonstrated | No dose adjustment required |
| Oral contraceptives | Hormonal contraception | Severe diarrhoea from prucalopride may reduce absorption of oral contraceptives | Use additional contraception if severe diarrhoea occurs |
| Digoxin | Cardiac glycoside | Increased colonic transit may reduce absorption of slow-release or enteric-coated formulations | Monitor digoxin levels; clinical significance is low |
Unlike older prokinetic agents (such as cisapride and tegaserod), prucalopride is highly selective for the 5-HT4 receptor and has minimal affinity for other serotonin receptor subtypes, hERG potassium channels, or cardiac ion channels. This selectivity profile means that prucalopride does not share the cardiac safety concerns (QT prolongation) that led to the withdrawal of cisapride and tegaserod from many markets. Thorough QT studies have shown no clinically relevant effect of prucalopride on the QT interval at therapeutic doses.
What Is the Correct Dosage of Prucalopride Holsten?
Because Prucalopride Holsten is only available in the 1 mg strength, the standard adult dose of 2 mg once daily is achieved by taking two 1 mg tablets together once a day. Elderly patients (over 65 years), those with severe liver disease, and those with severe kidney disease should take only one 1 mg tablet daily. The tablets can be taken at any time of day, with or without food.
Always take Prucalopride Holsten exactly as your doctor or pharmacist has told you. Do not change the dose on your own. Take your tablet(s) every day for as long as your doctor prescribes it. Your doctor will want to reassess your condition and the benefit of continued treatment after the first four weeks, and at regular intervals after that.
Adults (18–65 years)
Standard Adult Dosage
The recommended dose is 2 mg prucalopride once daily, which corresponds to two 1 mg Prucalopride Holsten tablets taken together. Swallow the tablets whole with a glass of water. The dose may be taken at any time of day, with or without food. For best results, try to take your tablets at the same time each day. Taking a higher dose than recommended will not improve the effect of the medicine but may increase the risk of side effects.
Elderly Patients (Over 65 Years)
Elderly Dosage
The starting dose for patients older than 65 years is 1 mg once daily (one tablet). If tolerated and if the clinical response is insufficient, your doctor may increase the dose to 2 mg once daily (two tablets). This reduced starting dose accounts for the potential for decreased kidney function and altered drug distribution commonly seen in elderly patients.
Patients with Severe Kidney Disease
Renal Impairment Dosage
If you have severe kidney disease (but do not require dialysis), the recommended dose is 1 mg once daily (one tablet). Prucalopride is partly eliminated by the kidneys, and reduced renal function can lead to higher drug levels in the blood. Patients requiring dialysis should not use Prucalopride Holsten.
Patients with Severe Liver Disease
Hepatic Impairment Dosage
If you have severe liver disease (Child-Pugh class C), the starting dose is 1 mg once daily (one tablet). Your doctor may increase this to 2 mg daily (two tablets) if needed and tolerated. Although prucalopride is not extensively metabolised by the liver, severe hepatic impairment may affect overall drug disposition.
| Patient Group | Starting Dose | Maximum Dose | Notes |
|---|---|---|---|
| Adults (18–65 years) | 2 mg (2 tablets) once daily | 2 mg (2 tablets) once daily | Standard dose; reassess after 4 weeks |
| Elderly (>65 years) | 1 mg (1 tablet) once daily | 2 mg (2 tablets) once daily | May increase if tolerated and needed |
| Severe kidney disease | 1 mg (1 tablet) once daily | 1 mg (1 tablet) once daily | Not for dialysis patients |
| Severe liver disease | 1 mg (1 tablet) once daily | 2 mg (2 tablets) once daily | May increase if tolerated and needed |
| Children (<18 years) | Not recommended | Not recommended | Safety and efficacy not established |
What to Do If You Miss a Dose
If you forget to take Prucalopride Holsten, do not take a double dose to make up for the missed one. Simply skip the missed dose and take your next dose at the usual time the following day. Taking a double dose will not improve the effectiveness of the medication and may increase the risk of side effects such as diarrhoea and headache.
Overdose
If you have taken more Prucalopride Holsten than prescribed, or if a child has accidentally ingested the medication, seek medical advice immediately by contacting your doctor, hospital emergency department, or poison control centre. Symptoms of overdose may include diarrhoea, headache, and nausea. If diarrhoea occurs following an overdose, ensure adequate fluid intake to prevent dehydration. There is no specific antidote for prucalopride; treatment is supportive and symptomatic.
What Happens If You Stop Taking Prucalopride Holsten
If you stop taking Prucalopride Holsten, your constipation symptoms are likely to return. There is no known withdrawal syndrome associated with stopping prucalopride, but the underlying chronic constipation will not have been cured by the medication. If you wish to discontinue treatment, discuss this with your doctor first, as they may recommend alternative management strategies or a gradual transition to other therapies.
What Are the Side Effects of Prucalopride Holsten?
Like all medicines, Prucalopride Holsten can cause side effects, although not everyone will experience them. The most common side effects are headache, nausea, diarrhoea, and abdominal pain. These side effects typically occur at the beginning of treatment and usually resolve within a few days of continued use.
Side effects of prucalopride are generally mild to moderate in severity and are most prominent during the first day or two of treatment. The gastrointestinal side effects (nausea, diarrhoea, abdominal pain) are consistent with the drug's mechanism of action – stimulating bowel motility – and tend to subside as the body adjusts to the medication. In clinical trials, the overall incidence of side effects was higher in the first week of treatment than in subsequent weeks.
Very Common
- Headache
- Nausea
- Diarrhoea
- Abdominal (stomach) pain
Common
- Decreased appetite
- Dizziness
- Vomiting
- Indigestion (dyspepsia)
- Flatulence (gas)
- Abnormal bowel sounds
- Fatigue
Uncommon
- Tremor
- Migraine
- Vertigo (spinning sensation)
- Palpitations – if you experience palpitations, inform your doctor
- Rectal bleeding
- Increased urination frequency (pollakiuria)
- Fever
- Feeling generally unwell (malaise)
Rare / Post-marketing Reports
- Allergic reactions (skin rash, pruritus)
- Severe abdominal cramping
The clinical significance of palpitations reported with prucalopride has been extensively evaluated. Unlike earlier prokinetic agents, prucalopride does not prolong the QT interval on electrocardiogram (ECG) at therapeutic doses. Thorough QT/QTc studies in healthy volunteers showed no clinically relevant effect on cardiac repolarisation. The European Medicines Agency (EMA) has concluded that the cardiovascular safety profile of prucalopride is reassuring.
If you experience any side effects that are severe, persistent, or concerning, consult your doctor, pharmacist, or nurse. This includes any side effects not listed above. You can also report suspected side effects directly to your national pharmacovigilance authority, which helps to monitor the ongoing safety profile of medicines.
Although rare, seek immediate medical attention if you develop signs of a severe allergic reaction (anaphylaxis) such as difficulty breathing, swelling of the face, lips, tongue, or throat, or severe skin reactions. Also contact your doctor promptly if you experience severe or persistent diarrhoea leading to dehydration, or if you notice rectal bleeding.
How Should You Store Prucalopride Holsten?
Store Prucalopride Holsten in its original packaging to protect from moisture. Keep it out of the sight and reach of children. Do not use after the expiry date printed on the blister pack and carton.
Proper storage of medications is essential to maintain their effectiveness and safety. Follow these guidelines for storing Prucalopride Holsten:
- Keep out of reach and sight of children – store the medication in a secure location where children cannot access it
- Check the expiry date – do not use Prucalopride Holsten after the expiry date (EXP) printed on the blister pack and outer carton. The expiry date refers to the last day of the stated month
- Store in the original packaging – the blister packs are moisture-sensitive, so keep the tablets in their original packaging until you are ready to take them
- No special temperature requirements – store at room temperature; no specific temperature limits are stated, but avoid extreme heat or cold
- Proper disposal – do not throw unused medicines in the wastewater or household waste. Return any unused or expired medication to your pharmacy for safe disposal to help protect the environment
What Does Prucalopride Holsten Contain?
The active ingredient in Prucalopride Holsten is prucalopride succinate, equivalent to 1 mg of prucalopride per tablet. The tablets also contain several inactive ingredients (excipients) that help form the tablet and its protective film coating.
Active Ingredient
Each film-coated tablet contains prucalopride succinate, corresponding to 1 mg of prucalopride. Prucalopride succinate is the salt form of prucalopride used in the tablet formulation to improve stability and bioavailability.
Inactive Ingredients (Excipients)
The other ingredients are:
- Tablet core: Lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate
- Film coating: Hypromellose (HPMC), macrogol (polyethylene glycol), polysorbate 80, titanium dioxide (E171)
Appearance and Pack Sizes
Prucalopride Holsten 1 mg tablets are small, round, film-coated tablets. The tablets are designed to be swallowed whole with water. The medicine is typically supplied in blister packs of varying sizes – commonly 7, 14, 28, or 84 tablets – to support flexible prescribing and to allow once-daily dosing over a defined treatment period. Not all pack sizes may be marketed in your country.
Marketing Authorisation Holder and Manufacturer
Prucalopride Holsten is distributed by Holsten Pharma GmbH, an established European pharmaceutical company that specialises in high-quality generic medicines. It is authorised within the European Economic Area (EEA) as a generic equivalent of the originator product Resolor (developed by Shire/Takeda). Both products contain the same active ingredient and have demonstrated bioequivalence, meaning they are absorbed into the body at the same rate and to the same extent.
Frequently Asked Questions About Prucalopride Holsten
Prucalopride Holsten and Resolor both contain the same active ingredient (prucalopride succinate). Prucalopride Holsten is a generic version distributed by Holsten Pharma, while Resolor is the original brand-name product. Generic medicines must demonstrate bioequivalence to the originator product, meaning they are absorbed into the body at the same rate and to the same extent. Both products are equally effective and safe for treating chronic constipation.
Prucalopride Holsten is marketed exclusively as 1 mg film-coated tablets. Because the standard adult dose is 2 mg once daily, most patients take two 1 mg tablets together each day. This single-strength approach provides flexibility: the same pack can be used for the full 2 mg dose (two tablets) as well as the reduced 1 mg dose (one tablet) for elderly patients or those with severe kidney or liver disease. Your doctor or pharmacist will confirm the exact number of tablets you should take.
Yes, prucalopride can be taken alongside laxatives if your doctor recommends it. In fact, prucalopride is specifically designed for patients in whom laxatives alone have not worked sufficiently. However, always follow your doctor's advice regarding the combination of medicines. Some patients may continue using occasional laxatives as needed while taking prucalopride, while others may find that prucalopride alone is sufficient to manage their constipation.
Many patients experience improvement within the first 24 hours of taking their first dose. In clinical studies, a significant proportion of patients had a spontaneous bowel movement within the first day. However, the full benefit of prucalopride may take several days to become apparent as regular bowel habits are established. Your doctor will assess the response after four weeks to determine whether to continue treatment.
No, prucalopride is not habit-forming and does not cause physical dependence. You will not experience withdrawal symptoms if you stop taking it. However, your constipation symptoms will likely return because the medication treats the symptoms of chronic constipation but does not cure the underlying condition. Your doctor will advise you on long-term management.
Prucalopride has been extensively studied for cardiovascular safety. Unlike older prokinetic agents (such as cisapride), prucalopride is highly selective for the 5-HT4 receptor and does not affect cardiac ion channels or prolong the QT interval. Thorough QT studies have confirmed its cardiac safety at therapeutic doses. Some patients may experience palpitations, but these are generally benign. If you experience persistent palpitations, inform your doctor.
There is no specific interaction between prucalopride and alcohol documented in the prescribing information. However, alcohol can worsen some of the side effects of prucalopride, such as dizziness, nausea, and headache, particularly during the first days of treatment. It is generally advisable to limit alcohol consumption while taking any medication and to consult your doctor if you have specific concerns.
References and Medical Sources
- European Medicines Agency (EMA). “Resolor (prucalopride) – Summary of Product Characteristics.” European Medicines Agency, last updated 2024. Available at: www.ema.europa.eu
- Camilleri M, Kerstens R, Rykx A, Vandeplassche L. “A placebo-controlled trial of prucalopride for severe chronic constipation.” New England Journal of Medicine. 2008;358(22):2344–2354.
- Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. “Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.” Gut. 2009;58(3):357–365.
- American Gastroenterological Association (AGA). “AGA Clinical Practice Guideline on the Pharmacological Management of Chronic Idiopathic Constipation.” Gastroenterology. 2023;165(4):1086–1097.
- National Institute for Health and Care Excellence (NICE). “Prucalopride for the treatment of chronic constipation in women.” Technology Appraisal TA211, updated 2023. Available at: www.nice.org.uk
- Quigley EMM, Vandeplassche L, Kerstens R, Ausma J. “Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study.” Alimentary Pharmacology & Therapeutics. 2009;29(3):315–328.
- World Health Organization (WHO). “WHO Model List of Essential Medicines – 23rd edition.” World Health Organization, 2023.
- Bouras EP, Camilleri M, Burton DD, et al. “Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.” Gastroenterology. 2001;120(2):354–360.
- British National Formulary (BNF). “Prucalopride.” Joint Formulary Committee, London: BMJ Group and Pharmaceutical Press, 2024.
- Holsten Pharma GmbH. “Prucalopride Holsten 1 mg film-coated tablets – Patient Information Leaflet.” Last revised 2024.
Editorial Team
Medical Review
This article has been reviewed by the iMedic Medical Review Board, comprising board-certified gastroenterologists and clinical pharmacologists with expertise in gastrointestinal motility disorders and pharmacotherapy.
Evidence Standards
All medical content follows the GRADE evidence framework and is based on peer-reviewed clinical trials, systematic reviews, and international guidelines from the AGA, NICE, EMA, and WHO.
Editorial Independence
iMedic maintains complete editorial independence. We receive no funding from pharmaceutical companies, and our content is free from commercial influence.
Update Policy
This article is reviewed and updated regularly to reflect the latest medical evidence. Last reviewed: January 2026. Next review due: July 2026.